Newsletter
Morphle Labs, a deep-tech healthcare company has raised $5 million in their Series A round led by Inflexor Ventures.
The Bengaluru-based company builds robotic microscopes and automated platforms for pathology labs, diagnostic centres, and healthcare facilities.
The deets: with fresh capital, the company aims to expand its presence globally and push production for its flagship products RoboTome and MorphoLens. It also aims to focus on gaining global regulatory approvals, attain IP leadership, and enhance tech-development.
For context, RoboTome is a robotic machine that cuts biopsy samples into very thin slices.It works more than twice as fast as an experienced lab technician.
MorphoLens is a scanner that can quickly convert these slices into digital images.It can scan over 100 slides in an hour using advanced lenses and AI-powered imaging.
Why it matters: Morphle Labs is tackling one of the most underserved yet crucial areas of healthcare by bringing automation to histopathology, the backbone of cancer diagnosis.
Globally, more than 60% of histopathology labs are operating with vacant positions, creating mounting backlogs, slower reports, and serious delays in patient treatment.
India’s histology market is also on a steep growth path, expected to rise 17.1% and reach $1,354.5 million by 2030. This gives Morphle a strong home-ground opportunity to scale while simultaneously building momentum for global expansion.
Grand View Research
